Novel cationic lipid compound as well as preparation method and application thereof

Through the combination of new cationic lipid compounds and phospholipids, sterols and PEG lipids, high-efficiency lipid carriers and nanoparticles were prepared, solving the problem of single cationic lipid structure in the prior art, and achieving efficient encapsulation of nucleic acid drugs and delivery have enhanced the application potential of nucleic acid preventive agents and therapeutic agents.

CN118993989APending Publication Date: 2024-11-22HUBEI GEDIAN HUMANWELL PHARMA EXCIPENTS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411078778.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the prior art, the cationic lipid structure is single, and it is difficult to meet the effective delivery of nucleic acid drugs, genetic vaccines, small molecule drugs, polypeptides or protein drugs, especially the development and application of nucleic acid preventive agents and therapeutic agents.

Method used

Provide a novel cationic lipid compound and its preparation method. By synthesizing cationic lipid compounds with specific structures and combining them with phospholipids, sterols and PEG lipids, high-efficiency lipid carriers and nanoparticles for use in nucleic acid molecules encapsulation and delivery.

Benefits of technology

The encapsulation efficiency and delivery effect of nucleic acid molecules are improved, and the development and application of nucleic acid preventive agents and therapeutic agents are provided more, especially in the delivery of nucleic acid drugs such as mRNA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118993989A_ABST
    Figure CN118993989A_ABST
Patent Text Reader

Abstract

The invention discloses a novel cationic lipid compound as well as a preparation method and application thereof. The present invention provides a compound I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, in which R1 and R2 are independently a C6-C30 alkyl group or a C6-C30 alkenyl group. The compound I, the stereoisomer thereof or the pharmaceutically acceptable salt thereof provided by the invention is a novel LNP lipid, and the carrier prepared from the compound I has very high encapsulation efficiency on nucleic acid molecules. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical chemical industry, and in particular to a novel cationic lipid compound, a preparation method and application thereof. Background Art

[0002] mRNA is a naturally occurring molecule that carries the "blueprint" of human cells and can produce target proteins or immunogens to activate the body's immune response to fight various pathogens. mRNA vaccines use the genetic sequence of the virus rather than the virus itself. Therefore, mRNA vaccines do not contain viral components and have no risk of infection. At the same time, mRNA vaccines also have a short research and development cycle and can quickly develop new candidate vaccines to respond to viral mutations; dual mechanisms of humoral immunity and T cell immunity, strong immunogenicity, no need for adjuvants, and easy mass production. In 2021, both Pfizer and Moderna's Covid-19 vaccines use a unique LNP delivery system that allows mRNA to enter the human body and exert a positive effect. The main role in this is played by cationic lipids. Ionizable cationic lipids usually have a tertiary amine that is deprotonated under neutral conditions and is positively charged under pH conditions below the lipid acid dissociation constant (pKa). Cationic lipids have two key functions: one is to promote nucleic acid encapsulation in LNPs; the other is to mediate the destruction of endosomal membranes to release nucleic acids into the cytoplasm. In addition, cationic lipids can also play an important role in endosomal uptake: either directly through the interaction between the positive charges on certain lipids and the negatively charged cell membrane, or through binding to plasma proteins that support cellular uptake. Summary of the invention

[0003] The problem to be solved by the present invention is to overcome the single structure of cationic lipids in the prior art and provide a new type of cationic lipid compound and a preparation method thereof, enrich the types of cationic lipid compounds, and provide more options for the effective delivery of nucleic acid drugs, gene vaccines, small molecule drugs, polypeptides or protein drugs, which is of great significance to the development and application of nucleic acid preventive and therapeutic agents.

[0004] The present invention provides a compound I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0005]

[0006] in,

[0007] R 1 and R 2 Independently C6-C 30 Alkyl or C 6- C 30 Alkenyl.

[0008] In some embodiments of the present invention, R 1 and R 2 Medium, C6-C 30 The alkyl groups are independently C 6-24 Alkyl, such as straight or branched C 9-17 Alkyl, preferably branched C 9-16 alkyl.

[0009] In some embodiments of the present invention, R 1 and R 2 Medium, C6-C 30 The alkenyl groups are independently C 6-24 Alkenyl, such as straight-chain or branched C 12-17 Alkenyl, preferably a straight or branched C 16-17 Alkenyl.

[0010] In some embodiments of the present invention, R 1 and R 2 Independently

[0011]

[0012]

[0013] In some embodiments of the present invention, R 1 and R 2 same.

[0014] In some embodiments of the present invention, the compound I is any of the following compounds:

[0015]

[0016]

[0017] The present invention provides a use of the compound I, its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of a nucleic acid preventive agent and / or therapeutic agent delivery vector.

[0018] In some embodiments of the present invention, the nucleic acid preventive and / or therapeutic agent is one or more of single-stranded deoxyribonucleic acid (DNA), double-stranded DNA, small interfering RNA (siRNA), asymmetric double-stranded small interfering RNA (aiRNA), microRNA (miRNA), small hairpin RNA (shRNA), circular RNA (circRNA), transfer RNA (tRNA) or messenger RNA (mRNA), preferably mRNA, such as human erythropoietin (hEPO) mRNA, firefly luciferase (Fluc) mRNA, SARS-CoV-2 spike protein (Spike) mRNA, herpes zoster virus (VZV) mRNA, respiratory syncytial virus (RSV) mRNA or influenza virus (Flu) mRNA.

[0019] The present invention provides a method for preparing compound I, which comprises the following steps:

[0020]

[0021] The present invention also provides a lipid carrier, which includes a substance Z, wherein the substance Z is the compound I as described above or a pharmaceutically acceptable salt thereof.

[0022] In some embodiments of the present invention, the lipid carrier further comprises phospholipids, sterols and PEG lipids.

[0023] In some embodiments of the present invention, the phospholipid may be a conventional phospholipid in the art, which is an amphiphilic auxiliary molecule that helps the fusion of lipid particles and cell membranes. The phospholipid may be distearoylphosphatidylcholine (DSPC), dimyristoylphosphocholine (DMPC), dioleoylphosphocholine (DOPC), palmitoylphosphocholine (DPPC) or 1,2-distearoylphosphocholine (DSPC).

[0024] In some embodiments of the present invention, the sterol may be a conventional sterol in the art, and the sterol may be selected from one or more of cholesterol, sitosterol, ergosterol, campesterol, stigmasterol, ursolic acid and α-tocopherol, such as cholesterol.

[0025] In some embodiments of the present invention, the PEG lipid may be a lipid molecule with a polyethylene glycol hydrophilic end modification. The PEG lipid may be one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol, such as PEG-modified dimyristoylglycerol (DMG-PEG2000).

[0026] In some embodiments of the present invention, the lipid carrier comprises the compound I, 1,2-distearoylphosphocholine (DSPC), cholesterol and PEG-modified dimyristoylglycerol (DMG PEG2000).

[0027] In some embodiments of the present invention, in the lipid carrier, the molar ratio of the substance Z, phospholipid, sterol and PEG lipid is (40-60):(5-15):(30-50):(0.5-3).

[0028] In some embodiments of the present invention, in the lipid carrier, the molar ratio of the substance Z, phospholipid, sterol and PEG lipid is 50:10:38.5:1.5.

[0029] In some embodiments of the present invention, in the lipid carrier, the molar ratio of Compound I, 1,2-distearoylphosphocholine (DSPC), cholesterol and PEG-modified dimyristoylglycerol (DMG PEG2000) is 50:10:38.5:1.5.

[0030] The present invention also provides a lipid nanoparticle, which comprises a nucleic acid preventive agent and / or a therapeutic agent and the aforementioned lipid carrier.

[0031] In some embodiments of the present invention, the nucleic acid preventive and / or therapeutic agent is as described above.

[0032] In some embodiments of the present invention, the particle size (average particle size) of the lipid nanoparticles is 10-100 nm, preferably 50-70 nm, such as 61.23 nm, 63.21 nm, 60.15 nm, 58.92 nm or 59.73 nm.

[0033] In some embodiments of the present invention, the encapsulation efficiency of the lipid nanoparticles is 85%-100%, such as 98.1%, 97.2%, 96.7%, 96.5% or 88.9%.

[0034] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0035] The reagents and raw materials used in the present invention are commercially available.

[0036] The positive and progressive effects of the present invention are:

[0037] (1) The present invention provides a novel LNP lipid;

[0038] (2) The vector prepared by the cationic lipid compound of the present invention has high encapsulation efficiency for nucleic acid molecules. DETAILED DESCRIPTION

[0039] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0040] In the specific embodiments of the present invention, the raw materials used can be obtained commercially.

[0041]

[0042] Example 1: Preparation of cationic lipid 1

[0043] Step 1: Preparation of intermediate 1-1

[0044]

[0045] Add 100 mL of dichloromethane, triethanolamine (59.6 g, 400 mmol), and triethylamine (56 mL, 400 mmol) into a flask and stir to dissolve. Control the temperature at 0°C, add a dichloromethane (400 ml) solution of TBSCl (12.1 g, 80.3 mmol) dropwise, keep warm for 2 hours, concentrate to remove dichloromethane, add 400 mL of ethyl acetate, wash with saturated sodium bicarbonate aqueous solution (400 mL*2), and finally wash once with saturated brine (400 mL), dry over anhydrous sodium sulfate, concentrate, and purify by silica gel column chromatography (dichloromethane: methanol = 19:1) to obtain intermediate 1-1 with a yield of 90%.

[0046] 1 HNMR (400MHz, CDCl3): 4.16 (s, 2H), 3.89 (t, 2H), 3.42 (t, 4H), 2.57 (t, 6H), 0.91 (s, 9H), 0.18 (s, 6H).

[0047] Step 2: Preparation of intermediate 1-2

[0048]

[0049] To a solution of 2-heptyldecanoic acid (6.49 g, 24 mmol, 2.4 eq) and intermediate 1-1 (2.63 g, 10.0 mmol, 1.0 eq) in dichloromethane (30 mL), DMAP (403.6 mg, 3.34 mmol, 0.4 eq) was added. After the mixture was stirred at room temperature for 5 minutes, EDCI (5.70 g, 28.94 mmol, 3.6 eq) was added, and the reaction mixture was stirred at room temperature overnight, and then TLC showed that the starting alcohol disappeared completely. The reaction mixture was diluted with DCM (300 mL) and washed with saturated NaHCO (100 mL), water (100 mL) and brine (100 mL). The combined organic layers were dried over Na2SO4 and the solvent was removed in vacuo to give a crude product, which was purified by column chromatography (silica gel, eluent: 0-1% EA (volume percentage) in n-hexane) and the pure product fractions were evaporated to give intermediate 1-2 (4.45 g, yield 58%).

[0050] 1 HNMR (400MHz, CDCl3): 4.20(t,4H), 3.91(t,2H), 3.06(t,6H), 2.13(m,2H) , 1.62(m,8H), 1.18-1.24(m,44H), 1.02(s,9H), 0.88(t,12H), 0.51(s,6H).

[0051] Step 3: Preparation of intermediate 1-3

[0052]

[0053] Add intermediate 1-2 (3.91 g, 5 mmol), THF (50 mL), and TBAF trihydrate (2.36 g, 7.5 mmol) into a flask, heat and reflux for 8 hours, concentrate to remove THF, add 50 mL of ethyl acetate, wash 3 times with 50 mL of water, dry over anhydrous sodium sulfate, filter, and concentrate to obtain intermediate 1-3 (3.27 g, 100% yield).

[0054] 1 HNMR (400MHz, CDCl3): 4.45(s,1H), 4.18(t,4H), 3.98(t,2H), 3.02(t,6H), 2.08(m,2H), 1.58(m,8H), 1.16-1.24(m,44H), 0.88(t,12H).

[0055] Step 4: Preparation of cationic lipid 1

[0056]

[0057] The intermediate 1-3 (3.34 g, 5 mmol), 4-dimethylaminopiperidine (768 mg, 6 mmol), triphosgene (2.23 g, 7.5 mmol) and 50 mL of dichloromethane were mixed, and the reaction solution was stirred at room temperature for 6 hours, 1 mL of water was added and stirred, concentrated, and purified by chromatography column. The eluent (petroleum ether: ethyl acetate = 4:1) was added with 1% triethylamine to obtain the finished compound cationic lipid 1 (3.74 g, yield 88%, purity 98%).

[0058] HNMR (400MHz, CDCl3): 4.42(t,2H), 4.21(t,4H), 3.55(t,4H), 2.98(t,6H), 2.71(t,1H), 2. 27(s,6H), 2.18(m,2H), 1.85~1.54(m,4H), 1.62(m,8H), 1.18~1.22(m,44H), 0.89(t,12H).

[0059] Example 2: Preparation of cationic lipid 2

[0060] Step 1: Synthesis of intermediate 2-2

[0061]

[0062] To a solution of 2-pentyl octanoic acid (5.14 g, 24 mmol, 2.4 eq) and intermediate 1-1 (2.63 g, 10.0 mmol, 1.0 eq) in dichloromethane (30 mL), DMAP (403.6 mg, 3.34 mmol, 0.4 eq) was added. After the mixture was stirred at room temperature for 5 minutes, EDCI (5.70 g, 28.94 mmol, 3.6 eq) was added, and the reaction mixture was stirred at room temperature overnight, and then TLC showed that the starting alcohol disappeared completely. The reaction mixture was diluted with DCM (300 mL) and washed with saturated NaHCO (100 mL), water (100 mL) and brine (100 mL). The combined organic layers were dried over Na2SO4 and the solvent was removed in vacuo to give a crude product, which was purified by column chromatography (silica gel column, eluent: 0-1% EA (volume percentage) in n-hexane) and the pure product fractions were evaporated to give intermediate 2-2 (3.67 g, yield 56%).

[0063] 1 HNMR (400MHz, CDCl3): 4.24(t,4H), 3.92(t,2H), 3.00(t,6H), 2.13(m,2H) , 1.62(m,8H), 1.18-1.24(m,28H), 1.02(s,9H), 0.88(t,12H), 0.51(s,6H).

[0064] Step 2: Synthesis of intermediate 2-3

[0065]

[0066] Intermediate 2-2 (3.28 g, 5 mmol), THF (50 mL), and TBAF trihydrate (2.36 g, 7.5 mmol) were mixed, and the reaction solution was then heated to reflux for 8 hours, concentrated to remove THF, 50 mL of ethyl acetate was added, washed three times with 50 mL of water, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain intermediate 2-3 (2.5 g, 100% yield).

[0067] 1 HNMR (400MHz, CDCl3): 4.58(s,1H), 4.20(t,4H), 3.98(t,2H), 3.02(t,6H), 2.08(m,2H), 1.58(m,8H), 1.16-1.24(m,28H), 0.88(t,12H).

[0068] Step 3: Preparation of cationic liposome 2

[0069]

[0070] The intermediate 2-3 (2.57 g, 5 mmol), 4-dimethylaminopiperidine (768 mg, 6 mmol), triphosgene (2.23 g, 7.5 mmol) and 50 mL of dichloromethane were mixed, and the reaction solution was stirred at room temperature for 6 hours, 1 mL of water was added and stirred, concentrated, and purified by chromatography column. The eluent (petroleum ether: ethyl acetate = 4:1) was added with 1% triethylamine to obtain the finished compound cationic lipid 2 (2.96 g, yield 85%, purity 99%).

[0071] 1 HNMR (400MHz, CDCl3): 4.43(t,2H), 4.20(t,4H), 3.55(t,4H), 2.98(t,6H), 2.68(t, 1H), 2.28(s,6H), 2.16(m,2H), 1.83~1.54(m,4H), 1.21~1.24(m,28H), 0.87(t,12H).

[0072] Example 3: Preparation of cationic lipid 3

[0073] Step 1: Synthesis of intermediate 3-2

[0074]

[0075] To a solution of 2-butyl hexanoic acid (4.13 g, 24 mmol, 2.4 eq) and intermediate 1-1 (2.63 g, 10.0 mmol, 1.0 eq) in dichloromethane (30 mL), DMAP (403.6 mg, 3.34 mmol, 0.4 eq) was added. After the mixture was stirred at room temperature for 5 minutes, EDCI (5.70 g, 28.94 mmol, 3.6 eq) was added, and the reaction mixture was stirred at room temperature overnight, and then TLC showed that the initiator alcohol disappeared completely. The reaction mixture was diluted with DCM (300 mL) and washed with saturated NaHCO (100 mL), water (100 mL) and brine (100 mL). The combined organic layers were dried over Na2SO4 and the solvent was removed in vacuo to give a crude product, which was purified by column chromatography (silica gel column, eluent: 0-1% EA (volume percentage) in n-hexane) and the pure product fractions were evaporated to give intermediate 3-2 (3.67 g, yield 60%).

[0076] 1 HNMR (400MHz, CDCl3): 4.20(t,4H), 3.91(t,2H), 3.06(t,6H), 2.13(m,2H) , 1.62(m,8H), 1.18-1.24(m,16H), 1.01(s,9H), 0.88(t,12H), 0.50(s,6H).

[0077] Step 2: Synthesis of intermediate 3-3

[0078]

[0079] Intermediate 3-2 (2.86 g, 5 mmol), THF (50 mL), and TBAF trihydrate (2.36 g, 7.5 mmol) were mixed, the reaction solution was heated to reflux for 8 hours, concentrated to remove THF, 50 mL of ethyl acetate was added, washed three times with 50 mL of water, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain intermediate 3-3 (2.28 g, 100% yield).

[0080] 1 HNMR (400MHz, CDCl3): 4.58(s,1H), 4.21(t,4H), 4.02(t,2H), 3.12(t,6H), 2.12(m,2H), 1.58(m,8H), 1.16-1.24(m,16H), 0.88(t,12H).

[0081] Step 3: Preparation of cationic liposomes

[0082]

[0083] The intermediate 3-3 (2.28 g, 5 mmol), 4-dimethylaminopiperidine (768 mg, 6 mmol), triphosgene (2.23 g, 7.5 mmol) and 50 mL of dichloromethane were mixed, and the reaction solution was stirred at room temperature for 6 hours, 1 mL of water was added and stirred, concentrated, and purified by chromatography column. The eluent (petroleum ether: ethyl acetate = 4:1) was added with 1% triethylamine to obtain the finished compound cationic lipid 3 (2.72 g, yield 89%, purity 99%).

[0084] 1 HNMR (400MHz, CDCl3): 4.45(t,2H), 4.22(t,4H), 3.56(t,4H), 2.98(t,6H), 2.68(t,1H), 2. 26(s,6H), 2.14(m,2H), 1.85~1.56(m,4H), 1.60(m,8H), 1.25~1.29(m,16H), 0.88(t,12H).

[0085] Example 4: Preparation of cationic liposome 4

[0086] Step 1: Synthesis of intermediate 4-2

[0087]

[0088] To a solution of (5E)-2-heptyldec-5-enoic acid (6.43 g, 24 mmol, 2.4 eq) and intermediate 1-1 (2.63 g, 10.0 mmol, 1.0 eq) in dichloromethane (30 mL), DMAP (403.6 mg, 3.34 mmol, 0.4 eq) was added. After the mixture was stirred at room temperature for 5 minutes, EDCI (5.70 g, 28.94 mmol, 3.6 eq) was added, and the reaction mixture was stirred at room temperature overnight, and then TLC showed that the starting material alcohol disappeared completely. The reaction mixture was diluted with DCM (300 mL) and washed with saturated NaHCO (100 mL), water (100 mL) and brine (100 mL). The combined organic layers were dried over Na2SO4 and the solvent was removed in vacuo to give a crude product, which was purified by column chromatography (silica gel column, eluent: 0-1% EA (volume percentage) in n-hexane) and the pure product fractions were evaporated to give intermediate 4-2 (4.28 g, yield 54%).

[0089] 1HNMR (400MHz, CDCl3): 5.48 (m, 4H), 4.20 (t, 4H), 3.91 (t, 2H), 3.06 (t, 6H), 2.13-2.21 (m, 6H) , 1.95(m,4H), 1.62(m,8H), 1.26-1.36(m,28H), 1.01(s,9H), 0.88-0.92(t,12H), 0.50(s,6H).

[0090] Step 2: Synthesis of intermediate 4-3

[0091]

[0092] Intermediate 4-2 (3.82 g, 5 mmol), THF (50 mL), and TBAF trihydrate (2.36 g, 7.5 mmol) were mixed, and the reaction solution was then heated to reflux for 8 hours, concentrated to remove THF, 50 mL of ethyl acetate was added, washed three times with 50 mL of water, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain intermediate 4-3 (3.25 g, 100% yield).

[0093] 1 HNMR (400MHz, CDCl3): 5.48 (m, 4H), 4.58 (s, 1H), 4.38 (t, 2H), 4.08 (t, 4H), 3.06 (t, 6H), 2.13-2.21(m,6H), 1.95(m,4H), 1.62(m,8H), 1.28-1.34(m,28H), 0.90(t,12H).

[0094] Step 3: Preparation of cationic liposomes 4

[0095]

[0096] The intermediate 4-3 (2.28 g, 5 mmol), 4-dimethylaminopiperidine (768 mg, 6 mmol), triphosgene (2.23 g, 7.5 mmol) and 50 mL of dichloromethane were mixed, and the reaction solution was stirred at room temperature for 6 hours, 1 mL of water was added and stirred, concentrated, and purified by chromatography column. The eluent (petroleum ether: ethyl acetate = 4:1) was added with 1% triethylamine to obtain the finished compound cationic lipid 4 (3.30 g, yield 82%, purity 98%).

[0097] 1HNMR (400MHz, CDCl3): 5.45(m,4H), 4.38(t,2H), 4.18(t,4H), 3.58(t,4H), 2.98(t,6H), 2.68(m,1H), 2. 27(s,6H), 2.18(m,6H), 1.90(m,4H), 1.85~1.58(m,4H), 1.62(m,8H), 1.26~1.34(m,28H), 0.90(t,12H).

[0098] Example 5: Preparation of cationic liposome 5

[0099] Step 1: Synthesis of intermediate 5-2

[0100]

[0101] To (10Z)-octadecene-9-enoic acid (6.78g, 24mmol, 2.4eq) and intermediate 1-1 (2.63g, 10.0mmol, 1.0eq) in dichloromethane (30mL) solution, DMAP (403.6mg, 3.34mmol, 0.4eq) was added. After the mixture was stirred at room temperature for 5 minutes, EDCI (5.70g, 28.94mmol, 3.6eq) was added, and the reaction mixture was stirred at room temperature overnight, and then TLC showed that the initiator alcohol disappeared completely. The reaction mixture was diluted with DCM (300mL), and washed with saturated NaHCO (100mL) aqueous solution, water (100mL) and saturated brine (100mL). The combined organic layers were dried over Na2SO4 and the solvent was removed in vacuo to give a crude product, which was purified by column chromatography (silica gel column, eluent: 0-1% EA (volume percentage) in n-hexane), and the pure product fractions were evaporated to give intermediate 5-2 (4.04 g, yield 51%).

[0102] 1 HNMR (400MHz, CDCl3): 5.38 (m, 4H), 4.32 (t, 2H), 4.20 (t, 4H), 2.98 (t, 6H), 2.32 (t, 4H) , 2.15(m,8H), 1.66(m,4H), 1.26-1.38(m,40H), 1.01(s,9H), 0.90(t,6H), 0.50(s,6H).

[0103] Step 2: Synthesis of intermediate 5-3

[0104]

[0105] Intermediate 5-2 (3.96 g, 5 mmol), THF (50 mL) and TBAF trihydrate (2.36 g, 7.5 mmol) were mixed, and the reaction solution was then heated to reflux for 8 hours, concentrated to remove THF, 50 mL of ethyl acetate was added, washed three times with 50 mL of water, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain intermediate 5-3 (3.39 g, 100% yield).

[0106] 1 HNMR (400MHz, CDCl3): 5.42 (m, 4H), 4.50 (s, 1H), 4.38 (t, 2H), 4.12 (t, 4H), 3.00 (t,6H), 2.32(t,4H), 2.10(m,8H), 1.62(m,4H), 1.28-1.34(m,40H), 0.90(t,6H).

[0107] Step 3: Preparation of cationic liposomes 5

[0108]

[0109] Intermediate 5-3 (3.39 g, 5 mmol), 4-dimethylaminopiperidine (768 mg, 6 mmol), triphosgene (2.23 g, 7.5 mmol), 50 mL of dichloromethane, stirred at room temperature for 6 hours, added 1 mL of water and stirred, concentrated, purified by chromatography column, eluted with eluent (petroleum ether: ethyl acetate = 4:1, plus 1% triethylamine), to obtain the finished compound cationic lipid 5 (3.24 g, yield 78%, purity 98%).

[0110] 1 HNMR (400MHz, CDCl3): 5.38(m,4H), 4.38(t,2H), 4.18(t,4H), 3.58(t,4H), 2.98(t,6H), 2.68(m,1H), 2 .32(t,4H), 2.20(s,6H), 2.12(m,8H), 1.83~1.58(m,4H), 1.68(m,4H), 1.26~1.34(m,40H), 0.90(t,6H).

[0111] Effect Example 1

[0112] The cationic lipid compounds of Examples 1 to 5 were dissolved in ethanol with DSPC, cholesterol and DMG-PEG2000 at a molar ratio of 50:10:38.5:1.5 to prepare an ethanol lipid solution, and human erythropoietin (hEPO) mRNA (from GenScript Biotech Co., Ltd.) was diluted in 10 to 50 mM citrate buffer (pH = 4) to obtain an mRNA aqueous solution. The ethanol lipid solution and the mRNA aqueous solution were mixed in a volume ratio of 1:3 using a microfluidic device to prepare liposomes with a total lipid to mRNA weight ratio of about 15 to 30:1. The ethanol was removed by static dialysis for 12-24 hours and replaced with DPBS. Finally, the lipid nanoparticles were filtered through a sterile filter to obtain an LNP preparation of human erythropoietin (hEPO) mRNA encapsulated with cationic lipid / DSPC / cholesterol / DMG-PEG2000 (50 / 10 / 38.5 / 1.5 mol%).

[0113] The size and polydispersity index (PDI) of lipid nanoparticles were determined by dynamic light scattering using a Malvern Zetasizer Nano ZS (Malvern UK) in 173° backscattering detection mode. The test results are shown in Table 1.

[0114] The encapsulation efficiency of lipid nanoparticles was determined using the Quant-it Ribogreen RNA quantification kit (Thermo Fisher Scientific, UK). The test results are shown in Table 1.

[0115] Table 1

[0116] Lipid Nanoparticles Cationic lipid compounds used Size(nm) PDI Encapsulation efficiency 1 Lipid 1 61.23 0.142 98.1% 2 Lipid 2 63.21 0156 97.2% 3 Lipid 3 60.15 0.133 96.7% 4 Lipid 4 58.92 0.125 96.5% 5 Lipid 5 59.73 0.103 88.9%

[0117] The experimental results show that the carrier prepared by using the cationic lipid compound of the present invention has high encapsulation efficiency for nucleic acid molecules and can construct a new type of LNP lipid.

Claims

1. A compound I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, It is characterized in that in, R 1 and R 2 Independently for C 6 -C 30 Alkyl or C 6- C 30 Alkenyl.

2. Compound I according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that R 1 and R 2 Independently for C 6 -C 24 Alkyl or C 6- C 24 Alkenyl.

3. Compound I according to claim 2, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that R 1 and R 2 In the C 6 -C 24 The alkyl groups are independently linear or branched C 9-17 Alkyl, preferably branched C 9-16 alkyl; and / or, R 1 and R 2 In the C 6 -C 24 Alkenyl is independently a straight or branched chain C 12-17 Alkenyl, preferably a straight or branched C 16-17 Alkenyl.

4. Compound I according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that R 1 and R 2 Independently 5. Compound I according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that R 1 and R 2 same.

6. Compound I according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, It is characterized in that The compound I is any of the following compounds:

7. Use of the compound I, its stereoisomer or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 6 in the preparation of a nucleic acid preventive agent and / or therapeutic agent delivery vector, It is characterized in that in, The nucleic acid preventive and / or therapeutic agent is preferably one or more of single-stranded deoxyribonucleic acid, double-stranded DNA, small interfering RNA, asymmetric double-stranded small interfering RNA, microRNA, small hairpin RNA, circular RNA, transfer RNA or messenger RNA, preferably mRNA, such as human erythropoietin mRNA, firefly luciferase mRNA, SARS-CoV-2 spike protein mRNA, herpes zoster virus mRNA, respiratory syncytial virus mRNA or influenza virus mRNA.

8. A method for preparing the compound I according to any one of claims 1 to 6, It is characterized in that It includes the following steps:

9. A lipid carrier, It is characterized in that It includes a substance Z, wherein the substance Z is the compound I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6; Preferably, the lipid carrier further comprises phospholipids, sterols and PEG lipids; Wherein, the phospholipid is preferably distearoylphosphatidylcholine, dimyristoylphosphocholine, dioleoylphosphocholine, palmitoylphosphocholine or 1,2-distearoylphosphocholine; The sterol is preferably one or more of cholesterol, sitosterol, ergosterol, campesterol, stigmasterol, ursolic acid and α-tocopherol, such as cholesterol; The PEG lipid is preferably one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol and PEG-modified dialkylglycerol, such as PEG-modified dimyristoylglycerol; Preferably, the molar ratio of the substance Z, phospholipid, sterol and PEG lipid is (40-60):(5-15):(30-50):(0.5-3); for example, the molar ratio of the substance Z, phospholipid, sterol and PEG lipid is 50:10:38.5:1.5; Further, the lipid carrier may include the compound I, 1,2-distearoylphosphocholine, cholesterol and PEG-modified dimyristoylglycerol; Preferably, the molar ratio of compound I, 1,2-distearoylphosphocholine (DSPC), cholesterol and PEG-modified dimyristoylglycerol is 50:10:38.5:1.

5.

10. A lipid nanoparticle, It is characterized in that It comprises a nucleic acid preventive and / or therapeutic agent and a lipid carrier as claimed in claim 9; Wherein, the nucleic acid preventive agent and / or therapeutic agent is preferably as described in claim 7; Preferably, the average particle size of the lipid nanoparticles is 10-100 nm, preferably 50-70 nm, such as 61.23 nm, 63.21 nm, 60.15 nm, 58.92 nm or 59.73 nm; Preferably, the encapsulation efficiency of the lipid nanoparticles is 85%-100%, such as 98.1%, 97.2%, 96.7%, 96.5% or 88.9%.